Scleromyxedema: Successful treatment with IVIg and lenalidomide

Authors

  • Jyotsna Oak Consultant Physician & Rheumatologist, Kokilaben Dhirubhai Ambani Hospital, Andheri, Mumbai 400053 INDIA
  • Sandeep Goyale Consultant, Oncologist, Kokilaben Dhirubhai Ambani Hospital, Mumbai.
  • Rupali Mathur Residents, Kokilaben Dhirubhai Ambani Hospital, Mumbai.
  • Vishal Haripara Residents, Kokilaben Dhirubhai Ambani Hospital, Mumbai.

DOI:

https://doi.org/10.15305/ijrci/v6i1/242

Abstract

Scleromyxedema is a rare progressive disorder associated with severe morbidity due to altered coarse facial features. The disease etiology is unknown. Various therapies have been investigated like the use of corticosteroids, IVIg (intravenous immunoglobulin), plasmapheresis, and thalidomide. The disorder being rare, evidence from controlled therapeutic trials is very limited. This report describes the case of a 37-year-old male with progressive scleromyxedema, without gammopathy. The patient was treated with prednisolone followed by IVIg. He showed remarkable improvement initially. Subsequent treatment with lenalidomide for one year showed complete resolution of the skin lesions with no side effects of the therapy.

References

Brown Falco O, Burgdor WHC, Wolff HH, Landthaaler M Lublin:Czelej; 2011 Dermatology; pp1289-90

Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus and scleromyxedema. J Am Acad Dermatol 2001;44:273-81

Serdar ZA, Yaser SP, Erfan GT, Gunnes P. Generalised papular sclerodermoid eruption: scleromyxedema. Indian J Dermatol Venerol Leprol 2010;76:592-2

Mehta V, Balchandran C, Raghavendra R, Arndt Gottron. Scleromyxedema: successful response to treatment with steroid minipulse and methotrexate. Indian J Dermatol 2009;54:193-5

Fesel AM, Donato ML, Duvic M. Complete remission of scleromyxoedema following autologuous stem cell transplantation.Arch Dermatol 2001;137:1071

Cokonis Georgakis CD, Falasca G ,Georgikis A, Hegmann WR. Scleromyxedema. Clin Dermatol 2006;24:493

Davies F, Baz R. Lenalidomide mode of action:linking bench and clinical finding. Blood Rev 2010;24(Suppl 1):513-9

Canueto J, Labrador J, Roman C, Santos-Briz A, Contreras T, Gutierrez NC, et al. The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxoedema: a rare disease with new clinical insights. Eur J Haematol 2012;88:450-454

Dinnen AM ,Dicken CH. Scleromyxoedema. J Am Acad Dermatol 1995;33:37-43

Saigoh S, Tashiro A, Fujita S, Matsui M. Successful treatment of intractable scleromyxoedema with cyclosporine A. Dematology 2003;207:410-411

Westheim AI, Lookingbill DP. Plasmapheresis in a patient with scleromyxoedema. Arch Dermatol1987;123:786-789.

Downloads

Additional Files

Published

12-06-2018

Issue

Vol. 6 No. 1 (2018)

Section

Case Studies

License

Copyright for articles published in this journal is retained by the authors, with first publication rights granted to the ‘Internet Journal of Rheumatology and Clinical Immunology’. All the published content, except where otherwise noted, is licensed under Creative Commons license (CC-BY).

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) after the publication of the manuscript in IJRCI, as it can lead to productive exchanges, as well as earlier and greater citation of published work.